


=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> d his

(FILE 'HOME' ENTERED AT 07:46:41 ON 27 JUL 2004)

FILE 'REGISTRY' ENTERED AT 07:46:54 ON 27 JUL 2004


L1 STRUCTURE UPLOADED
L2 1 S L1
L3 50 S L1 FULL
L4 50 S L3 AND CAPLUS/LC
L5 0 S L3 AND CAOLD/LC
L6 0 S L3 AND REF.CAPLUS>10

FILE 'CAPLUS' ENTERED AT 07:52:31 ON 27 JUL 2004

L7 3 S L3

L7 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2002:483072 CAPLUS
 DOCUMENT NUMBER: 137:47109
 TITLE: Preparation of trisubstituted indole derivatives for
 inhibiting neoplastic cells
 INVENTOR(S): Pamukcu, Rifat; Piazza, Gary A.
 PATENT ASSIGNEE(S): Cell Pathways, Inc., USA
 SOURCE: U.S., 76 pp., Cont.-in-part of U. S. 6,046,199.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6410584	B1	20020625	US 1998-199860	19981125
US 6046199	A	20000404	US 1998-7098	19980114
US 2002143022	A1	20021003	US 2002-71639	20020207
PRIORITY APPLN. INFO.:			US 1998-7098	A2 19980114
			US 1998-199860	A3 19981125
OTHER SOURCE(S):		MARPAT 137:47109		
GI				



AB Title compds. I [R¹-3 = H, alkyl, alkylthio alkoxy, with the proviso that R¹-3 are not simultaneously hydrogen atoms; R⁴ = H, alkyl; R⁵ = carboxy, an esterified carboxy group, or an amidated carboxy group] were prepared For instance, 6-methoxycarbonyl-2-methylindole was N-alkylated with 2-chlorobenzyl bromide (DMF, K₂CO₃, 80°C, 18 h); the product saponified and the resulting acid coupled to benzenesulfonamide (DMF, CDI, DBU) to afford II. I are used for inhibiting the growth of neoplastic cells (no data).


IT **206065-16-9P**, 5-((Benzenesulfonyl)carbamoyl)-3-(2,4-dichlorobenzyl)-2-methylindole **206065-31-8P**, 3-(2,4-Dichlorobenzyl)-5-[[[(4-methoxybenzene)sulfonyl]carbamoyl]-2-methylindole **206065-53-4P**, 3-(2,4-Dichlorobenzyl)-2-methyl-5-[[[(4-methylbenzene)sulfonyl]carbamoyl]indole **206065-55-6P**, 3-(2,4-Dichlorobenzyl)-2-methyl-5-[[[(4-nitrobenzene)sulfonyl]carbamoyl]indole **206065-57-8P**, 5-[[[(4-Chlorobenzene)sulfonyl]carbamoyl]-3-(2,4-dichlorobenzyl)-2-methylindole **206065-59-0P**, 5-[[[(3-Chlorobenzene)sulfonyl]carbamoyl]-3-(2,4-dichlorobenzyl)-2-methylindole **206065-61-4P**, 5-[[[(2-Chlorobenzene)sulfonyl]carbamoyl]-3-(2,4-dichlorobenzyl)-2-methylindole

yl]-3-(2,4-dichlorobenzyl)-2-methylindole 206065-63-6P,
 3-(2,4-Dichlorobenzyl)-5-[[4-(fluorobenzene)sulfonyl]carbamoyl]-2-
 methylindole 206065-64-7P, 3-(2,4-Dichlorobenzyl)-2-methyl-5-
 [[2-naphthalene)sulfonyl]carbamoyl]indole 206065-65-8P,
 3-(2,4-Dichlorobenzyl)-2-methyl-5-[[naphthalen-1-
 yl)sulfonyl]carbamoyl]indole 206065-66-9P, 3-(2,4-
 Dichlorobenzyl)-2-methyl-5-[[2-methylbenzene)sulfonyl]carbamoyl]indole
 206065-68-1P, 5-(((4-Bromobenzene)sulfonyl)carbamoyl)-3-(2,4-
 dichlorobenzyl)-2-methylindole 206065-70-5P,
 3-(2,4-Dichlorobenzyl)-2-methyl-5-[[4-(vinylbenzene)sulfonyl]carbamoyl]ind
 ole 206065-71-6P, 5-[[4-(Phenylazo)benzene)sulfonyl]carbamoyl]-
 3-(2,4-dichlorobenzyl)-2-methylindole 206065-72-7P,
 3-(2,4-Dichlorobenzyl)-2-methyl-5-[[4-(trifluoromethylbenzene)sulfonyl]car
 bamoyl]indole 206065-74-9P, 3-(2,4-Dichlorobenzyl)-5-[[3,4-
 dimethoxybenzene)sulfonyl]carbamoyl]-2-methylindole 206065-76-1P
 , 5-[[4-(tert-Butylbenzene)sulfonyl]carbamoyl]-3-(2,4-dichlorobenzyl)-2-
 methylindole 206065-77-2P, 3-(2,4-Dichlorobenzyl)-2-methyl-5-
 [[3-methylbenzene)sulfonyl]carbamoyl]indole 206065-81-8P,
 3-(2,4-Dichlorobenzyl)-2-methyl-5-[[4-(phenylbenzene)sulfonyl]carbamoyl]in
 dole 206065-83-0P, 5-((Benzenesulfonyl)carbamoyl)-3-[2-chloro-4-
 phenylbenzyl]-2-methylindole 206065-85-2P, 5-[[4-(n-
 Butylbenzene)sulfonyl]carbamoyl]-3-(2,4-dichlorobenzyl)-2-methylindole
 206065-86-3P, 5-[[4-(Butoxy)benzene)sulfonyl]carbamoyl]-3-(2,4-
 dichlorobenzyl)-2-methylindole 206065-96-5P,
 3-[(1-Bromonaphthalen-2-yl)methyl]-2-methyl-5-[[4-(
 vinylbenzene)sulfonyl]carbamoyl]indole 206065-98-7P,
 5-[[Benzenesulfonyl]carbamoyl]-3-[(1-bromonaphthalen-2-yl)methyl]-2-
 methylindole 206066-00-4P, 3-[2-Chloro-4-phenylbenzyl]-2-methyl-
 5-[[4-(vinylbenzene)sulfonyl]carbamoyl]indole 206066-02-6P,
 3-[2-Chloro-4-phenylbenzyl]-2-methyl-5-[[4-methylphenylsulfonyl]carbamoyl]
 indole 438003-21-5P, 3-(2,4-Dichlorobenzyl)-5-((2,5-
 dimethylbenzene)sulfonyl)carbamoyl]-2-methylindole 438003-26-0P,
 3-(2,4-Dichlorobenzyl)-5-[[4-ethylbenzene)sulfonyl]carbamoyl]-2-
 methylindole 438003-36-2P, 3-[(1-Bromonaphthalen-2-yl)methyl]-2-
 methyl-5-[[p-toluenesulfonyl]carbamoyl]indole
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(drug; preparation of trisubstituted indole derivs. for inhibiting
 neoplastic cells)


RN 206065-16-9 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-
 (phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 206065-31-8 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-N-[(4-
 methoxyphenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-53-4 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 206065-55-6 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-[(4-nitrophenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 206065-57-8 CAPLUS

CN 1H-Indole-5-carboxamide, N-[(4-chlorophenyl)sulfonyl]-3-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-59-0 CAPLUS

CN 1H-Indole-5-carboxamide, N-[(3-chlorophenyl)sulfonyl]-3-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 206065-61-4 CAPLUS


CN 1H-Indole-5-carboxamide, N-[(2-chlorophenyl)sulfonyl]-3-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 206065-63-6 CAPLUS


CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-N-[(4-

fluorophenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-64-7 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-(2-naphthalenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 206065-65-8 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-(1-naphthalenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 206065-66-9 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-[(2-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 206065-68-1 CAPLUS

CN 1H-Indole-5-carboxamide, N-[(4-bromophenyl)sulfonyl]-3-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-70-5 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-N-[(4-ethenylphenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-71-6 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-[[4-(phenylazo)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 206065-72-7 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-[[4-(trifluoromethyl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 206065-74-9 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-N-[(3,4-dimethoxyphenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-76-1 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-N-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-77-2 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-[(3-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 206065-81-8 CAPLUS


CN 1H-Indole-5-carboxamide, N-([1,1'-biphenyl]-4-ylsulfonyl)-3-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 206065-83-0 CAPLUS


CN 1H-Indole-5-carboxamide, 3-[(3-chloro[1,1'-biphenyl]-4-yl)methyl]-2-methyl-

N-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 206065-85-2 CAPLUS

CN 1H-Indole-5-carboxamide, N-[(4-butylphenyl)sulfonyl]-3-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-86-3 CAPLUS

CN 1H-Indole-5-carboxamide, N-[(4-butoxyphenyl)sulfonyl]-3-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-96-5 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(1-bromo-2-naphthalenyl)methyl]-N-[(4-ethenylphenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-98-7 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(1-bromo-2-naphthalenyl)methyl]-2-methyl-N-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 206066-00-4 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(3-chloro[1,1'-biphenyl]-4-yl)methyl]-N-[(4-ethenylphenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206066-02-6 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(3-chloro[1,1'-biphenyl]-4-yl)methyl]-2-methyl-N-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 438003-21-5 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-N-[(2,5-dimethylphenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 438003-26-0 CAPLUS


CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-N-[(4-ethylphenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 438003-36-2 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(1-bromo-2-naphthalenyl)methyl]-2-methyl-N-[(2-

methylphenyl)sulfonyl] - (9CI) (CA INDEX NAME)



REFERENCE COUNT:

18

THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1998:239201 CAPLUS

DOCUMENT NUMBER: 128:294695

TITLE: Preparation and formulation of indole derivatives as hypoglycemics and phosphodiesterase 5 inhibitors

INVENTOR(S): Yamasaki, Noritsugu; Imoto, Takafumi; Murai, Yoshiyuki; Hiramura, Takahiro; Onomura, Osamu; Nishikawa, Masahiro; Oku, Teruo; Sawada, Kouzou; Kayakiri, Hiroshi; et al.

PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 184 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese



FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9815530	A1	19980416	WO 1997-JP3592	19971007
W: AU, BR, CA, CN, HU, IL, JP, KR, MX, NZ, RU, SG, TR, US, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, NL, PT, SE				
AU 9744005	A1	19980505	AU 1997-44005	19971007
ZA 9708998	A	19980420	ZA 1997-8998	19971008
PRIORITY APPLN. INFO.:		JP 1996-287676	A	19961008
		JP 1997-187536	A	19970627
		WO 1997-JP3592	W	19971007

OTHER SOURCE(S): MARPAT 128:294695

GI



AB The title compds. I [R1 - R3 = H, alkyl, etc.; a proviso is given; R4 = H,

alkyl; R5 = carboxy, etc.] are prepared I are useful as remedies for impaired glucose tolerance, diabetes, complication of diabetes, insulin resistant syndrome, hyperlipidemia, atherosclerosis, cardiovascular diseases, hyperglycemia, hypertension; diseases characterized by angina pectoris, high blood pressure, pulmonary hypertension, congestive heart failure, glomerular diseases, tubular interstitial diseases, renal insufficiency, atherosclerosis, angiostenosis, peripheral vascular diseases, cerebral stroke, chronic reversible obstructive diseases, allergic rhinitis, urticaria, glaucoma or intestinal motility disorders; sexual impotence, osteoporosis, nephritis, cancerous cachexia or post-PTCA reconstruction. The title compound II at 10 mg/kg gave 46% decrease of blood sugar in mice.


IT 206065-16-9P 206065-31-8P 206065-53-4P
 206065-55-6P 206065-57-8P 206065-59-0P
 206065-61-4P 206065-63-6P 206065-64-7P
 206065-65-8P 206065-66-9P 206065-67-0P
 206065-68-1P 206065-70-5P 206065-71-6P
 206065-72-7P 206065-74-9P 206065-76-1P
 206065-77-2P 206065-81-8P 206065-83-0P
 206065-84-1P 206065-85-2P 206065-86-3P
 206065-96-5P 206065-97-6P 206065-98-7P
 206066-00-4P 206066-02-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of indole derivs. as hypoglycemics and phosphodiesterase 5 inhibitors)


RN 206065-16-9 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 206065-31-8 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-N-[(4-methoxyphenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-53-4 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 206065-55-6 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-[(4-nitrophenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 206065-57-8 CAPLUS

CN 1H-Indole-5-carboxamide, N-[(4-chlorophenyl)sulfonyl]-3-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-59-0 CAPLUS

CN 1H-Indole-5-carboxamide, N-[(3-chlorophenyl)sulfonyl]-3-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-61-4 CAPLUS

CN 1H-Indole-5-carboxamide, N-[(2-chlorophenyl)sulfonyl]-3-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-63-6 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-N-[(4-fluorophenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-64-7 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-(2-naphthalenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 206065-65-8 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-(1-naphthalenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 206065-66-9 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-[(2-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 206065-67-0 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-N-[(2,6-dimethylphenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-68-1 CAPLUS

CN 1H-Indole-5-carboxamide, N-[(4-bromophenyl)sulfonyl]-3-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-70-5 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-N-[(4-ethenylphenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-71-6 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-[[4-(phenylazo)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 206065-72-7 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-[[4-(trifluoromethyl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 206065-74-9 CAPLUS


CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-N-[(3,4-dimethoxyphenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 206065-76-1 CAPLUS


CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-N-[[4-(1,1-

dimethylethyl)phenyl]sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-77-2 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-[(3-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 206065-81-8 CAPLUS

CN 1H-Indole-5-carboxamide, N-([1,1'-biphenyl]-4-ylsulfonyl)-3-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-83-0 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(3-chloro[1,1'-biphenyl]-4-yl)methyl]-2-methyl-N-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 206065-84-1 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(3-chloro[1,1'-biphenyl]-4-yl)methyl]-N-[(4-ethylphenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-85-2 CAPLUS

CN 1H-Indole-5-carboxamide, N-[(4-butylphenyl)sulfonyl]-3-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-86-3 CAPLUS

CN 1H-Indole-5-carboxamide, N-[(4-butoxyphenyl)sulfonyl]-3-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-96-5 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(1-bromo-2-naphthalenyl)methyl]-N-[(4-ethenylphenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-97-6 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(1-bromo-2-naphthalenyl)methyl]-2-methyl-N-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 206065-98-7 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(1-bromo-2-naphthalenyl)methyl]-2-methyl-N-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 206066-00-4 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(3-chloro[1,1'-biphenyl]-4-yl)methyl]-N-[(4-ethenylphenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 206066-02-6 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(3-chloro[1,1'-biphenyl]-4-yl)methyl]-2-methyl-N-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

53

THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT